Oramed Pharmaceuticals (NASDAQ:ORMP) just reported results for the first quarter of 2024.
- Oramed Pharmaceuticals reported earnings per share of 4 cents. This was above the analyst estimate for EPS of 2 cents.
- The company did not report any revenue for the quarter.